Genentech has announced that a phase 3 study of its brand-name rituximab, Rituxan, met its primary end point and demonstrated that treatment with rituximab is superior to treatment with mycophenolate mofetil in patients with moderate to severe pemphigus vulgaris (PV), a rate autoimmune disease that affects the skin and mucous membranes.
Genentech has announced that a phase 3 study of its brand-name rituximab, Rituxan, met its primary end point and demonstrated that treatment with rituximab is superior to treatment with mycophenolate mofetil in patients with moderate to severe pemphigus vulgaris (PV), a rate autoimmune disease that affects the skin and mucous membranes.
In the PEMPHIX study, a double-blind, double-dummy, active-comparator, parallel arm study in patients requiring oral corticosteroids, patients were randomized to receive either rituximab plus a placebo or mycophenolate mofetil plus a placebo for 52 weeks along with steroids, with the aim of tapering the steroid dose to 0 by week 24.
The primary end point at week 52 was the percentage of participants who achieved sustained complete remission without treatment failure; the study met this end point, with 40.3% of patients treated with rituximab, versus just 9.5% of patients treated with mycophenolate mofetil, achieving sustained complete remission without steroids for 16 weeks or more (P = .0001).
Secondary end points also favored rituximab, says Genentech: Patients treated with the biologic had lower cumulative oral corticosteroid doses, fewer flares, a greater likelihood of sustained complete remission, a lower likelihood of flares, and greater improvements in quality of life. Adverse events were consistent with the known profile of rituximab.
The results were presented in a late-breaking oral presentation during the 28th Congress of the European Academy of Dermatology and Venereology in Madrid, Spain.
The FDA first approved the brand-name rituximab for PV in 2018 on the basis of a different phase 3 study, the Ritux 3 trial, which showed that rituximab plus corticosteroids was superior to corticosteroids alone as first-line treatment for patients with PV. As a results of the findings, the International Bullous Disease Consensus Group reached an international consensus to recommend rituximab and corticosteroids as first-line therapy for moderate to severe PV.
The newly reported data could help Genentech and its innovator drug stay ahead of biosimilar competition, at least in the PV market; notably, the 2 currently FDA-approved biosimilar rituximab products, Pfizer’s Ruxience and Celltrion’s Truxima, are not approved to treat PV. The biosimilars both have so-called “skinny labels” due to patent protections and exclusivities for the reference drug. Neither drug has yet announced a launch date for the US marketplace.
Biosimilar Market Development Requires Strategic Flexibility and Global Partnerships
April 29th 2025Thriving in the evolving biosimilar market demands bold collaboration, early global partnerships, and a fresh approach to development strategies to overcome uncertainty and drive future success.
How AI Can Help Address Cost-Related Nonadherence to Biologic, Biosimilar Treatment
March 9th 2025Despite saving billions, biosimilars still account for only a small share of the biologics market—what's standing in the way of broader adoption and how can artificial intelligence (AI) help change that?
President Trump Signs Executive Order to Bring Down Drug Prices
April 16th 2025To help bring down sky-high drug prices, President Donald Trump signed an executive order pushing for faster biosimilar development, more transparency, and tougher rules on pharmacy benefit managers—aiming to save billions and make meds more affordable for everyone.
Will the FTC Be More PBM-Friendly Under a Second Trump Administration?
February 23rd 2025On this episode of Not So Different, we explore the Federal Trade Commission’s (FTC) second interim report on pharmacy benefit managers (PBMs) with Joe Wisniewski from Turquoise Health, discussing key issues like preferential reimbursement, drug pricing transparency, biosimilars, shifting regulations, and how a second Trump administration could reshape PBM practices.